Results of a late-stage clinical trial suggest that an experimental immunotherapy may boost survival in people with melanoma. Called talimogene laherparepvec (T-VEC), the vaccine includes a gene called granulocyte-macrophage colony-stimulating factor (GM-CSF) that stimulates the immune system. The researchers found that people injected with T-VEC lived an average of 4 months longer than those treated with GM-CSF on its own (23 vs 19 mo). In addition, T-VEC made more tumors disappear or shrink by at least half.
Researchers report that a modified cold sore virus may help deliver longer lasting shrinkage of melanoma tumors. Called talimogene laherparepvec (T-VEC), the engineered virus kills cancer cells directly and boosts the immune response against them by tagging their surfaces with a protein called granulocyte macrophage colony-stimulating factor (GM-CSF). T-VEC outperformed GM-CSF (administered directly) in a phase III trial of 436 people with melanomas that had spread—tumors shrank more often (26% vs 6%) and were more likely to stay shrunk for at least 6 months (16% vs 2%). The researchers caution that while promising, T-VEC is unlikely to be a stand-alone treatment and suggest that this virus might ultimately be combined with another immunotherapy such as ipilimumab.
People with melanoma may live longer when treated with two drugs that boost the immune system, suggest early results from a clinical trial. The drugs are ipilimumab, which is FDA approved, and granulocyte-macrophage colony-stimulating factor (GM-CSF), which is experimental. In a phase II trial of 245 people with melanoma, more were alive at 1 year when treated with both drugs than when treated with ipilimumab alone (69% vs 53%). The combination treatment also helped alleviate the severe toxic side effects of ipilimumab, which dropped from 58% to 45%. These findings were among several advances in immunotherapy treatments for melanoma presented at the American Society of Clinical Oncology’s 2013 meeting.
A new immunotherapy known as talimogene laherparepvec (T-VEC), or Ovcovex GM-CSF, has shown the ability to shrink advanced melanoma tumors. T-VEC is a genetically modified version of herpes simplex virus type 1, the virus that causes cold sores. T-VEC was also engineered to produce GM-CSF (granulocyte-macrophage colony-stimulating factor), a protein that stimulates the immune system. Amgen, the California-based biopharmaceutical company that is developing the experimental cancer therapy, announced on March 19 that T-VEC had shown positive results in an advanced melanoma clinical trial. Continue reading…
A phase III trial suggests that a virus-based treatment could help control melanomas that have spread, according to the pharmaceutical firm Amgen. The treatment, called talimogene laherparepvec or TVEC, involves injecting tumors with a modified cold sore virus. The modifications make the virus grow in cancer cells, but not in normal cells, and make the cancer cells produce a protein called GM-CSF that stimulates the immune system. More than 250 people in the trial received TVEC injections every 2 weeks and tumors shrank in about 40 (16%) of those who were treated.